Abstract and Introduction
Introduction
Seasonal influenza vaccine is recommended for all pregnant women because of their increased risk for influenza-associated complications. In addition, receipt of influenza vaccine by women during pregnancy has been shown to protect their infants for several months after birth.[1] As part of its case-control surveillance study of medications and birth defects, the Birth Defects Study of the Slone Epidemiology Center at Boston University has recorded data on vaccinations received during pregnancy since the 2005–06 influenza vaccination season. Among the 5,318 mothers of infants without major structural birth defects (control newborns) in this population, seasonal influenza vaccination coverage was approximately 20% in the seasons preceding the 2009–10 pandemic H1N1 (pH1N1) influenza season. During the 2009–10 influenza vaccination season, influenza vaccination coverage among pregnant women increased to 33%, and has increased modestly since then, to 41% during the 2013–14 season. Among pregnant women who received influenza vaccine during the 2013–14 season, 80% reported receiving their vaccine in a traditional health care setting, (e.g., the office of their obstetrician or primary care physician or their prenatal clinic) and 20% received it in a work/school, pharmacy/supermarket, or government setting. Incorporating routine administration of seasonal influenza vaccination into the management of pregnant women by their health care providers might increase coverage with this important public health intervention.
Influenza poses a serious threat to public health. In the United States, millions of persons are sickened, and thousands die each year of influenza and influenza-related illness.[2,3] Because pregnant women infected with influenza are at increased risk for severe illness, hospitalization, and complications,[4] in 2004, the Advisory Committee on Immunization Practices (ACIP) updated their guidance with the recommendation that "women who will be pregnant during the influenza season" receive the seasonal influenza vaccine, regardless of pregnancy trimester.[5] In the influenza seasons after the ACIP recommendation (2006–07 through 2008–09), CDC estimated influenza vaccination coverage among pregnant women to be approximately 15%; coverage did not exceed 30% until it increased markedly (to 38%) during the 2009 H1N1 influenza pandemic.[6] The most recent CDC study on influenza vaccination among pregnant women (2015–16 influenza season) reported overall coverage of 50%; an estimated 14% of women were vaccinated ≤5–6 months before pregnancy and 36% were vaccinated during pregnancy.[7]
In 2006, the Birth Defects Study began to inquire specifically about receipt of influenza vaccine and other vaccines during pregnancy. The current report describes secular trends in seasonal influenza vaccination coverage among pregnant women in the Birth Defects Study during the nine seasons from 2005 through 2014, along with the settings in which pregnant women received their vaccinations.
The Birth Defects Study conducted surveillance during 1976–2015 using a case-control methodology described previously.[8] Infants with major structural birth defects (cases) were identified at study centers that, for the present analysis, included participating hospitals in the areas surrounding Boston, Massachusetts, Philadelphia, Pennsylvania, and San Diego, California, as well as birth defects registries in New York and Massachusetts. Infants without structural defects (controls) were randomly selected each month from study hospitals' discharge lists or statewide vital statistics records. Within 6 months of delivery, mothers of case and control infants were invited to participate in a computer-assisted telephone interview conducted by trained study nurses. Data were collected on demographic characteristics, lifestyle factors, reproductive history, illnesses, and medications used from 2 months before the last menstrual period (LMP) through the end of pregnancy. Medication data included prescription and over-the-counter drugs and, for pregnancies that began in 2005 or later, any vaccines received during pregnancy. Women were asked to provide an exact date of vaccination or, if the vaccination date was not available, a range of possible dates, along with the setting or facility where the vaccine was administered (e.g., doctor's office/prenatal clinic, workplace, school, pharmacy/supermarket, or government site). All women who reported receiving a vaccine were asked to provide a release allowing study personnel to contact the vaccine provider to validate their vaccine report. If vaccine records were not available, the maternal report was accepted.[9]
This analysis of influenza vaccination coverage was limited to pregnancies in control women that overlapped with the 2005–06 through 2013–14 influenza vaccine seasons. Each influenza vaccine season was defined as beginning on August 1 and continuing through July 31 of the following year. Among women who reported receiving influenza vaccine during pregnancy, the exact date of vaccination obtained from the vaccination record was used to assign the influenza vaccination season during which vaccine was received, if the record was available; otherwise, the vaccination date the woman provided or the midpoint of the reported date range was used. To ensure equivalent opportunity for vaccination during each influenza season, the range of LMP dates among women who received each season's vaccine was identified; women whose LMPs fell within that range but did not receive the vaccine were included in the analysis as unvaccinated women.
Among the 5,318 pregnant women who participated in the study during the nine influenza vaccination seasons (2005–06 through 2013–14), 73% of vaccine doses administered were validated by provider records; the remaining 27% were ascertained by maternal self-report. Influenza vaccination coverage varied by season (Figure). During the 2009–10 influenza vaccination season, pH1N1 vaccine became available late in the season as a separate product; in subsequent seasons, pH1N1 vaccine has been included as a component of seasonal influenza vaccines. During the 2005–06 through 2008–09 influenza vaccination seasons, coverage ranged from 17%–20%. Seasonal influenza vaccination coverage increased to 33% during the 2009–10 season and to 35% for the pH1N1 vaccine. Coverage declined slightly during the next two influenza vaccination seasons (2010–11 and 2011–12), to 31% and 27% respectively; subsequently, in the 2012–13 and 2013–14 seasons, coverage increased again to 35% and 41%, respectively.
Figure.
Receipt of seasonal influenza vaccine by pregnant women* participating in the Birth Defects Study† — United States, 2005–06 through 2013–14 influenza seasons
*Women participating as controls (i.e., mothers of infants without a structural birth defect).
†Participating hospitals in areas surrounding Boston, MA; Philadelphia, PA; and San Diego, CA; and birth defects registries in New York and Massachusetts.
Overall, 79% of influenza vaccinations received by pregnant women were administered in a traditional health care setting (e.g., the office of their obstetrician or primary care physician or their prenatal clinic). During the nine influenza vaccination seasons, the proportion of vaccine doses received by pregnant women in these settings increased from 73% during the 2005–06 season to 80% during the 2013–14 season. The proportion of vaccine doses received in pharmacy/supermarket settings increased from 4% in 2005–06 to 8% in 2013–14; the proportion of doses received at work or school decreased from 23% in 2006–07 to 10% in 2013–14.
Morbidity and Mortality Weekly Report. 2016;65(48):1370-1373. © 2016 Centers for Disease Control and Prevention (CDC)
